Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 15/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970864 | 0.88 | FGFR1 (0.49) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL29545927 | 0.85 | FGFR4 (0.65) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL3971330 | 0.82 | LCK (0.56) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL3975110 | 0.82 | FGFR4 (0.61) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL21166429 | 0.81 | FGFR4 (0.57) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL3970204 | 0.80 | FGFR4 (0.59) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL3977200 | 0.78 | FGFR1 (0.62) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21166432 | 0.76 | FGFR4 (0.64) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16134035 | 0.74 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL3975789 | 0.73 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | FGFR4 95/4885FGFR1 55/4885FGFR2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.